This category page covers biotechnology and pharmaceutical companies developing therapies that modulate GABAergic signaling and address excitotoxicity — two interconnected mechanisms central to Alzheimer's disease pathophysiology. Excessive glutamate-mediated excitotoxicity causes calcium dysregulation and neuronal death, while GABAergic dysfunction contributes to network hyperexcitability, seizures, and cognitive impairment in AD. Several companies are now targeting these systems with novel mechanisms distinct from legacy benzodiazepines and first-generation NMDA antagonists[@gaba2024][@excito2024].
The main therapeutic approaches in this space include:
Excitotoxicity is a pathological process in which excessive glutamatergic signaling leads to neuronal damage and death. In Alzheimer's disease, multiple pathways converge to promote excitotoxic injury:
This category page covers biotechnology and pharmaceutical companies developing therapies that modulate GABAergic signaling and address excitotoxicity — two interconnected mechanisms central to Alzheimer's disease pathophysiology. Excessive glutamate-mediated excitotoxicity causes calcium dysregulation and neuronal death, while GABAergic dysfunction contributes to network hyperexcitability, seizures, and cognitive impairment in AD. Several companies are now targeting these systems with novel mechanisms distinct from legacy benzodiazepines and first-generation NMDA antagonists[@gaba2024][@excito2024].
The main therapeutic approaches in this space include:
Excitotoxicity is a pathological process in which excessive glutamatergic signaling leads to neuronal damage and death. In Alzheimer's disease, multiple pathways converge to promote excitotoxic injury:
GABAergic therapies counteract this by enhancing inhibitory tone, reducing network hyperexcitability, and protecting against calcium-mediated cell death.
Mechanism: Neurosteroid-based GABA-A receptor positive allosteric modulators and NMDA receptor antagonists
Clinical Stage: Phase 2 (SAGE-718 for AD cognitive impairment)
Background: Sage Therapeutics (acquired by [Biogen](/companies/biogen) in 2023 for $14.6B) pioneered the development of neurosteroid-based GABA-A receptor modulators. Their lead AD candidate, SAGE-718, is an NMDA receptor antagonist with a differentiated mechanism from ketamine — designed to provide cognitive benefits without dissociative or psychedelic effects. SAGE-718 is currently in Phase 2 trials for Alzheimer's disease cognitive impairment, Parkinson's disease dementia, and Huntington's disease cognitive impairment[@sage2024][@sage2023].
Key Pipeline:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| SAGE-718 | Alzheimer's disease (cognitive) | NMDA receptor antagonist | Phase 2 |
| SAGE-718 | Parkinson's disease dementia | NMDA receptor antagonist | Phase 2 |
| SAGE-718 | Huntington's disease | NMDA receptor antagonist | Phase 2 |
| SAGE-689 | CNS disorders | GABA-A PAM (neurosteroid) | Phase 1 |
Neurosteroid Platform: Sage's GABA-A modulators are built on allopregnanolone science. Unlike benzodiazepines that bind at the alpha-gamma interface, neurosteroid modulators bind at the beta subunit interface, offering different pharmacological profiles. In AD models, GABA-A PAMs reduce amyloid-beta-induced neurotoxicity and improve cognitive function[@lippman2021].
Company: [Sage Therapeutics](/companies/sage-therapeutics) (NASDAQ: SAGE, acquired by Biogen)
Status: Active development; SAGE-718 Phase 2 data anticipated 2025-2026
Mechanism: AMPA receptor modulators for synaptic plasticity and neuroprotection; anti-seizure drugs with neuroprotective potential
Clinical Stage: Phase 2 (SPN-820 for treatment-resistant depression; SPN-817 for epilepsy)
Background: Supernus Pharmaceuticals develops CNS treatments with a focus on movement disorders and epilepsy. Their portfolio includes SPN-820, an AMPA receptor modulator in development for treatment-resistant depression and potentially for cognitive impairment in AD. Additionally, Supernus markets anti-epileptic drugs (OXTELLAR XR, TROKENDI XR) that may provide neuroprotective benefits in AD given the high comorbidity of seizures in early-onset AD patients[@supernus2024][@supernus2023].
AD Relevance:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| SPN-820 | Treatment-resistant depression | AMPA modulator | Phase 2 |
| SPN-820 | Cognitive impairment (AD) | AMPA modulator | Preclinical |
| SPN-817 | Epilepsy | Anti-seizure (unknown target) | Phase 1 |
| SPN-830 | Parkinson's disease (OFF episodes) | Dopamine agonist | Phase 3 |
Company: [Supernus Pharmaceuticals](/companies/supernus-pharmaceuticals) (NASDAQ: SUPN)
Mechanism: LRRK2 kinase inhibitors (with glutamate system interactions); neuroinflammation modulators; early glutamate transporter programs
Clinical Stage: Phase 1 (AZD-5004 LRRK2 inhibitor for PD; glutamate programs in research)
Background: [AstraZeneca](/companies/astrazeneca) maintains active neuroscience research programs including glutamate transporter enhancers and NMDA receptor modulators. Their LRRK2 inhibitor program (AZD-5004) is in Phase 1 for Parkinson's disease, but LRRK2 biology intersects with glutamate signaling pathways — LRRK2 mutations affect synaptic function and glutamate receptor trafficking[@astrazeneca2024].
AD Research Programs:
Mechanism: Alpha2delta calcium channel modulators; LRRK2 inhibitors; glutamate system modulators
Clinical Stage: Various (mirogabalin approved; LRRK2 inhibitor in Phase 1; glutamate programs in research)
Background: [Daiichi Sankyo](/companies/daiichi-sankyo) has a broad neuroscience portfolio with programs targeting ion channels and kinase pathways relevant to excitability and neuroprotection. Mirogabalin (Tarlige), their alpha2delta calcium channel subunit modulator, is approved for neuropathic pain in Japan, EU, and US. Alpha2delta subunits are also expressed in brain regions relevant to AD, and calcium channel modulation can reduce excitatory neurotransmitter release[@daiichi2024].
AD Pipeline:
| Program | Target/Mechanism | Indication | Stage |
|---------|-----------------|------------|-------|
| DS-1211 | TNF receptor | Neurodegeneration | Preclinical |
| DA-9801 | Unknown | Alzheimer's disease | Preclinical |
| DS-2120 | Alpha-synuclein modulator | Parkinson's disease | Preclinical |
| Mirogabalin | Alpha2delta calcium channel | Neuropathic pain (approved) | Marketed |
Company: [Daiichi Sankyo](/companies/daiichi-sankyo) (TYO: 4568)
Mechanism: Multi-target CNS drugs; lumateperone affects serotonin, dopamine, glutamate, and GABA receptors
Clinical Stage: Marketed (CAPLYTA); AD psychosis indication in development
Background: [Intra-Cellular Therapies](/companies/intra-cellular-therapies) markets CAPLYTA (lumateperone) for schizophrenia and bipolar depression. Lumateperone has a unique polypharmacology — it acts as a serotonin 5-HT2A receptor antagonist, dopamine D2 receptor partial agonist, and also modulates glutamate signaling through indirect NMDA receptor modulation. Clinical trials are underway for Alzheimer's disease psychosis, where excitotoxicity and GABAergic dysfunction both contribute to psychotic symptoms[@intracellular2024].
AD Relevance:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| CAPLYTA (lumateperone) | Alzheimer's disease psychosis | Multi-receptor modulator (5-HT2A, D2, NMDA, GABA) | Phase 3 |
| ITI-214 | Parkinson's disease | Phosphodiesterase 1 inhibitor | Phase 1/2 |
| ITI-333 | Pain and addiction | Multi-target opioid receptor modulator | Phase 1 |
Company: [Intra-Cellular Therapies](/companies/intra-cellular-therapies) (NASDAQ: ITCI)
Mechanism: GABA-A receptor positive allosteric modulators; anti-amyloid antibodies
Clinical Stage: SAGE-718 Phase 2 (via Sage acquisition); aducanumab on market
Background: Following the $14.6B acquisition of [Sage Therapeutics](/companies/sage-therapeutics) in 2023, [Biogen](/companies/biogen) inherited Sage's full CNS pipeline including SAGE-718 for AD cognitive impairment. Biogen's existing portfolio includes aducanumab (Aduhelm) and lecanemab for amyloid clearance, and the addition of Sage's GABA/NMDA modulators creates a complementary approach to AD treatment[@biogen2024].
GABA/NMDA Programs via Sage:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| SAGE-718 | Alzheimer's disease (cognitive) | NMDA receptor antagonist | Phase 2 |
| SAGE-718 | Parkinson's disease dementia | NMDA receptor antagonist | Phase 2 |
| SAGE-324 | Essential tremor | GABA-A PAM | Phase 2 |
| SAGE-689 | CNS disorders | GABA-A PAM | Phase 1 |
Company: [Biogen](/companies/biogen) (NASDAQ: BIIB)
Mechanism: NMDA receptor antagonists; sigma-1 receptor agonists; TRP channel modulators
Clinical Stage: Phase 3 (AXS-06 for depression; AXS-07 for migraine); AD programs in development
Background: [Axsome Therapeutics](/companies/axsome-therapeutics) develops novel CNS drugs with NMDA antagonist and sigma-1 receptor agonist mechanisms relevant to AD. AXS-06 (esmethadone) is an NMDA receptor antagonist in Phase 3 for treatment-resistant depression, and its mechanism may translate to AD cognitive impairment. The company also has programs targeting sigma-1 receptors, which are involved in ER stress, mitochondrial function, and neuroprotection — pathways relevant to excitotoxic damage[@axsome2024].
AD Pipeline:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| AXS-06 | Treatment-resistant depression (AD cognitive overlap) | NMDA antagonist | Phase 3 |
| AXS-07 | Migraine (AD comorbidity) | Multi-mechanism (NSAID + 5-HT1F) | Phase 3 |
| AXS-12 | Narcolepsy | Norepinephrine reuptake inhibitor | Phase 2 |
| AD program | Alzheimer's disease | TBD | Discovery |
Company: [Axsome Therapeutics](/companies/axsome-therapeutics) (NASDAQ: AXSM)
Mechanism: Anti-epileptic drugs with GABAergic mechanisms; Brivaracetam (SV2A modulator); novel sodium channel modulators
Clinical Stage: Brivaracetam marketed; novel programs in AD research
Background: [UCB Pharma](/companies/ucb-pharma) has a long history of GABAergic drug development through its anti-epileptic portfolio. Brivaracetam (Upstreax/Breliv) is a synaptic vesicle protein 2A (SV2A) modulator that reduces glutamate release and has demonstrated neuroprotective properties in pre-clinical AD models. UCB's epilepsy drugs are particularly relevant given the high prevalence of seizures in early-onset familial AD, and their GABAergic mechanisms may provide direct neuroprotective benefits[@ucb2024].
AD Relevance:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| Brivaracetam | Epilepsy (AD comorbidity) | SV2A modulator | Marketed |
| UCB-7246 | Parkinson's disease | Anti-seizure/neuroprotection | Preclinical |
Company: [UCB Pharma](/companies/ucb-pharma) (Euronext Brussels: UCB)
Mechanism: Selective serotonin 2A receptor inverse agonists; GABA-A PAM partnerships
Clinical Stage: Pimavanserin marketed (PDP); AD psychosis in Phase 3
Background: [Acadia Pharmaceuticals](/companies/acadia-pharmaceuticals) markets pimavanserin (Nuplazid) for Parkinson's disease psychosis, with a growing AD psychosis program. While pimavanserin acts primarily at 5-HT2A receptors (inverse agonist), its mechanism reduces cortical hyperexcitability, similar to some GABAergic effects. Acadia has also explored GABA-A receptor modulators for cognitive impairment[@acadia2024].
AD Programs:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| Pimavanserin | Alzheimer's disease psychosis | 5-HT2A inverse agonist | Phase 3 |
| ACP-204 | Alzheimer's disease psychosis | 5-HT2A antagonist | Phase 1 |
| Novel program | Cognitive impairment (AD) | GABA-A PAM | Discovery |
Company: [Acadia Pharmaceuticals](/companies/acadia-pharmaceuticals) (NASDAQ: ACAD)
Mechanism: GABA-B receptor agonists; glutamate antagonists; anti-epileptic drugs
Clinical Stage: Various; Gabaxodil in Phase 2 for PD; anti-epileptic portfolio for AD comorbidity
Background: [Lundbeck](/companies/lundbeck) has a focused CNS portfolio with multiple programs relevant to excitotoxicity and GABAergic modulation. Gabaxodil (oral gabapentin analog) is in Phase 2 for Parkinson's disease, leveraging GABAergic mechanisms to address motor complications. Lundbeck's anti-epileptic portfolio (including brivaracetam via UCB partnership) has crossover applications in AD given seizure comorbidity[@lundbeck2024].
Pipeline:
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| Gabaxodil | Parkinson's disease (dyskinesia) | GABA-B agonist | Phase 2 |
| Desmethyllofexidine | Tremor | Alpha-2 agonist | Phase 2 |
| Brivaracetam | Epilepsy (AD comorbidity) | SV2A modulator | Marketed (via UCB) |
Company: [Lundbeck](/companies/lundbeck) (CPH: LUN)
Mechanism: GABA-B receptor agonists; VMAT2 inhibitors for movement disorders
Clinical Stage: Ongentys (opicapone) marketed; valbenazine for tardive dyskinesia; GABA-B programs in development
Background: [Neurocrine Biosciences](/companies/neurocrine-biosciences) focuses on disorders of the brain and endocrine system. Their GABA-B receptor agonist programs have potential applications in AD, as GABA-B agonism reduces glutamate release, provides neuroprotection, and may improve cognitive function in pre-clinical AD models[@neurocrine2024].
AD Relevance:
The GABA/excitotoxicity therapy space for AD is characterized by: